BR0207706A - ésteres de diaminoquinazolina para uso como inibidores da diidrofolato redutase - Google Patents

ésteres de diaminoquinazolina para uso como inibidores da diidrofolato redutase

Info

Publication number
BR0207706A
BR0207706A BR0207706-0A BR0207706A BR0207706A BR 0207706 A BR0207706 A BR 0207706A BR 0207706 A BR0207706 A BR 0207706A BR 0207706 A BR0207706 A BR 0207706A
Authority
BR
Brazil
Prior art keywords
esters
dihydrofolate reductase
diaminoquinazoline
reductase inhibitors
inhibitors
Prior art date
Application number
BR0207706-0A
Other languages
English (en)
Inventor
Torbjoern Lundstedt
Anneli Haellgren
Per Andersson
Anders Hallberg
Malin Graffner Nordberg
Original Assignee
Melacure Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0100694A external-priority patent/SE0100694D0/xx
Priority claimed from SE0200008A external-priority patent/SE0200008D0/xx
Application filed by Melacure Therapeutics Ab filed Critical Melacure Therapeutics Ab
Publication of BR0207706A publication Critical patent/BR0207706A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"éSTERES DE DIAMINOQUINAZOLINA PARA USO COMO INIBIDORES DA DIIDROFOLATO REDUTASE". A presente invenção refere-se aos compostos da fórmula (I), em que R~ 1~, R~ 2~, R~ 1~' e R~ 2~' são independentemente hidrogênio ou um grupo que libera a amina livre in vivo, R~ 6~ é uma fenila substituída ou um sistema de anéis de arila opcionalmente substituídos, bicíclicos ou tricíclicos, ou um sistema de anéis de heteroarila opcionalmente substituídos, mono, bi- ou tricíclicos, tendo utilidade como inibidores da diidrofolato redutase (DHFR) com propriedades farmacocinéticas favoráveis.
BR0207706-0A 2001-02-28 2002-02-28 ésteres de diaminoquinazolina para uso como inibidores da diidrofolato redutase BR0207706A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0100694A SE0100694D0 (sv) 2001-02-28 2001-02-28 DHFR inhibitors
SE0200008A SE0200008D0 (sv) 2002-01-02 2002-01-02 New pharmaceutically compounds
PCT/GB2002/000888 WO2002068397A1 (en) 2001-02-28 2002-02-28 Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors

Publications (1)

Publication Number Publication Date
BR0207706A true BR0207706A (pt) 2004-03-23

Family

ID=26655401

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207706-0A BR0207706A (pt) 2001-02-28 2002-02-28 ésteres de diaminoquinazolina para uso como inibidores da diidrofolato redutase

Country Status (9)

Country Link
US (1) US20040092515A1 (pt)
EP (1) EP1366028A1 (pt)
JP (1) JP2004520414A (pt)
KR (1) KR20030086272A (pt)
BR (1) BR0207706A (pt)
CA (1) CA2439463A1 (pt)
IL (1) IL157597A0 (pt)
MX (1) MXPA03007699A (pt)
WO (1) WO2002068397A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032807A1 (en) * 2003-08-06 2005-02-10 Rosenwald Lindsay A. Methods of treating inflammatory diseases with ammonium salts of ornitihine derivatives
JP2009522246A (ja) * 2005-12-30 2009-06-11 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプターアンタゴニスト
GB0608822D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of DHFR
PT2054045E (pt) * 2006-08-16 2011-08-31 Action Medicines Sl Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor
US7550674B2 (en) 2007-02-22 2009-06-23 Nexans UTP cable
CN102482249B (zh) 2009-07-08 2016-06-08 德米拉(加拿大)公司 用于治疗皮肤病症或疾病状态的tofa类似物
EP3602041A4 (en) * 2017-03-23 2021-01-13 Meharry Medical College METHODS OF DIAGNOSIS AND TREATMENT OF INFLAMMATORY INTESTINAL DISEASE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108630A0 (en) * 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines

Also Published As

Publication number Publication date
EP1366028A1 (en) 2003-12-03
WO2002068397A1 (en) 2002-09-06
MXPA03007699A (es) 2004-03-16
KR20030086272A (ko) 2003-11-07
IL157597A0 (en) 2004-03-28
JP2004520414A (ja) 2004-07-08
US20040092515A1 (en) 2004-05-13
WO2002068397A8 (en) 2003-12-04
CA2439463A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
PH12013501489A1 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
ES2546502T3 (es) 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
BR0208179A (pt) Composto, composição farmacêutica, métodos para tratar distúrbios associados com o receptor 5-ht6, distúrbios cognitivos, distúrbios da mémoria, psicose, esquizofrenia, e ansiedade, e, uso de um composto
TN2011000244A1 (en) Organic compounds
GT200200069A (es) Derivados de mercaptoacetilamida, procedimiento para su preparacion y su uso
MA30709B1 (fr) Derives de pyrido (2, 3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3.
MX2009003129A (es) Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras.
SG154435A1 (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
SG151250A1 (en) Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
BRPI0818893B8 (pt) compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula
DE60214990D1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
AR058700A1 (es) Compuestos heterociclicos como bloqueadores del canal de sodio epitelial
ECSP088824A (es) Prolinamidas sustituidas, su preparación y su uso como medicamentos
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
CL2011000784A1 (es) Compuestos derivados de 7-h-pirazoli[3,4-e]-diasepina-6(5h)-ona sustituidos; procedimiento de preparacion; composicion farmaceutica, utiles como agentes antibacteriales.
GEP20146063B (en) Solid pharmaceutical composition
BR0318503A (pt) quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase
BR0207706A (pt) ésteres de diaminoquinazolina para uso como inibidores da diidrofolato redutase
TN2011000429A1 (en) Derivatives of benzothiazines, preparation thereof and application thereof as drugs
TW200740806A (en) Bridged N-cyclic sulfonamido inhibitors of gamma secretase
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
BR0213731A (pt) Compostos de silìcio
MX2008011576A (es) Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4O, 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.